Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022011132 - COMBINATION ANTI-CANCER PRODUCTS AND METHODS

Publication Number WO/2022/011132
Publication Date 13.01.2022
International Application No. PCT/US2021/040880
International Filing Date 08.07.2021
IPC
A61K 31/11 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
11Aldehydes
A61K 31/437 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
4353ortho- or peri-condensed with heterocyclic ring systems
437the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/12 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
12Ketones
A61K 45/06 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/4375 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
4353ortho- or peri-condensed with heterocyclic ring systems
4375the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • ANKH LIFE SCIENCES LIMITED [IE]/[IE] (AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BE, BF, BG, BH, BJ, BN, BR, BW, BY, BZ, CA, CF, CG, CH, CI, CL, CM, CN, CO, CR, CU, CY, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, FR, GA, GB, GD, GE, GH, GM, GN, GQ, GR, GT, GW, HN, HR, HU, ID, IE, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KM, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MC, MD, ME, MK, ML, MN, MR, MT, MW, MX, MY, MZ, NA, NE, NG, NI, NL, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SI, SK, SL, SM, SN, ST, SV, SY, SZ, TD, TG, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW)
  • CROW, Larry D. [US]/[US] (MG)
Inventors
  • ZAID, Gene H.
  • WEST, Cameron E.
  • DENT, Paul
  • MOORE, Robert Preston
Agents
  • COOK, Crissa A.
Priority Data
63/049,32208.07.2020US
63/188,20213.05.2021US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) COMBINATION ANTI-CANCER PRODUCTS AND METHODS
(FR) PRODUITS ANTI-CANCÉREUX COMBINÉS ET PROCÉDÉS
Abstract
(EN) Combination dosage forms of anti-cancer products include components a) and b), where component a) comprises individual amounts of curcumin, harmine, isovanillin, and component b) comprises an agent selected from the group consisting of EGFR inhibitors, CDK 4/6 inhibitors, 5-fluorouracil, checkpoint inhibitors, anti-metabolites, prodrugs thereof, and mixtures thereof. The products may be administered to mammalian subjects suffering from a variety of cancers, to provide a synergistic therapeutic effect.
(FR) La présente invention concerne des formes posologiques combinées de produits anticancéreux qui comprennent des composants a) et b), le composant a) comprenant des quantités individuelles de curcumine, d'harmine, d'isovanilline et le composant b) comprenant un agent sélectionné dans le groupe constitué des inhibiteurs de l'EGFR, des inhibiteurs de CDK 4/6, du 5-fluorouracile, des inhibiteurs de points de contrôle, des anti-métabolites, des promédicaments de ceux-ci, et des mélanges de ceux-ci. Les produits peuvent être administrés à des sujets mammifères souffrant d'une variété de cancers, pour fournir un effet thérapeutique synergique.
Latest bibliographic data on file with the International Bureau